Evidence map›Paper›PMID 42438221›Full record

ArticleDrug development research2026

Discovery of Novel PCSK9-LDLR PPI Inhibitors by a Structural Modification Approach.

Huan Zhu, Zhiqin Zhang, Lihui Zhang, Jiangying Cao, Lei Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug development research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Huan ZhuSchool of Pharmacy, Shandong Second Medical University, Weifang, Shandong, China.
Zhiqin ZhangSchool of Stomatology, Shandong Second Medical University, Weifang, Shandong, China.
Lihui ZhangSchool of Stomatology, Shandong Second Medical University, Weifang, Shandong, China.
Jiangying CaoSchool of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Lei ZhangSchool of Pharmacy, Shandong Second Medical University, Weifang, Shandong, China.ORCID https://orcid.org/0000-0002-6833-2488

Funding

Natural Science Foundation of Shandong Province ZR2022QH186
6 · The paper itself

Abstract

Proprotein convertase subtilisin/kexin 9 (PCSK9) mediating the degradation of the hepatic low-density lipoprotein receptor (LDLR), has emerged as a novel therapeutic target for the treatment of hyperlipidemia. Herein, to disrupt the protein-protein interactions (PPIs) between PCSK9 and LDLR, a total of 43 compounds were designed and synthesized by structural modification of previous derived PCSK9 inhibitors. In the PCSK9-LDLR PPI interfering test, compounds B7, B23, and B27 showed inhibitory potency with IC

Indexed as

PCSK9 InhibitorsProprotein Convertase 9Receptors, LDLDrug DesignDrug DiscoveryHep G2 CellsHumansMolecular Docking SimulationProtein BindingStructure-Activity RelationshipLDLR protein, humanPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9Receptors, LDLLDLLDLRPCSK9PPI inhibitorsmall molecule

Identifiers

PMID42438221
PMCPMC13358326

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.